2026
article
OpenAlex
Hubert B. Haywood, Uchechukwu Ikeaba, Gregg C Fonarow, Haolin Xu et autres
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure (HF).1,2 Outpatient clinic visits are an important opportunity to optimize guideline-directed medical therapy for the general HF population, as well as specific disease-modifying medications for those with ATTR-CM. Yet, large-scale …
us
(code pays fourni par la source)
2026
article
OpenAlex
Andrew Girard, Omar Cantu Martinez, Uchechukwu Ikeaba, Mohammad Abdel Jawad et autres
us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Trevor A. Lentz, Brooke Alhanti, Uchechukwu Ikeaba, Adam D. Lutz et autres
BACKGROUND: Musculoskeletal pain conditions are prevalent and costly, with practice guidelines consistently recommending non-pharmacologic interventions as first-line treatments. Physical therapists are common providers of non-pharmacologic pain care, and early access to their services is believed to reduce the risk of care intensification, …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Regina Royan, Uchechukwu Ikeaba, Brooke Alhanti, Brian J. Stamm et autres
Introduction: There is minimal real-world data on whether stroke process quality metrics differ for intracerebral hemorrhage (ICH) and acute ischemic stroke (AIS) and if they have changed over time. Identifying and addressing these differences may inform targeted quality improvement initiatives to optimize …
us, ca
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Hanzhang Xu, Brian Mac Grory, Uchechukwu Ikeaba, Brooke Alhanti et autres
BACKGROUND: About one in three COVID-19 patients experience neurological problems; and acute ischemic stroke (AIS) is one of the common comorbidities of COVID-19. As stroke doubles the risk of dementia, AIS patients with COVID-19 infection may experience even higher risk of developing …
us, ca
(code pays fourni par la source)
2025
article
OpenAlex
Satoshi Shoji, Uchechukwu Ikeaba, Gregg C. Fonarow, Senthil Selvaraj et autres
jp, us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Satoshi Shoji, Uchechukwu Ikeaba, Gregg C. Fonarow, Senthil Selvaraj et autres
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is associated with high risk for heart failure (HF) hospitalization. However, little is known regarding post-discharge outcomes and healthcare costs for patients with underlying ATTR-CM, as compared with the general HF population. Methods: We analyzed Medicare beneficiaries …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Trevor A. Lentz, Adam D. Lutz, Uchechukwu Ikeaba, Brooke Alhanti et autres
IMPORTANCE: New care models promoting early access to physical therapy by reducing or eliminating copays are emerging. Few studies have compared health care use in these programs to other care pathways across musculoskeletal conditions. OBJECTIVE: The objective of this study was to …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Trevor A. Lentz, Uchechukwu Ikeaba, Brooke Alhanti, Adam D. Lutz et autres
OBJECTIVES: To identify clustered trajectories of self-reported disability following the initiation of care by a physical therapist in outpatient orthopaedic settings and to determine baseline factors that distinguish between different trajectories. DESIGN: Retrospective cohort study using electronic health record and patient-reported outcome …
us
(code pays fourni par la source)
2025
article
OpenAlex
Hubert B. Haywood, Lisa A. Kaltenbach, Uchechukwu Ikeaba, Gregg C. Fonarow et autres
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Mohammad Abdel Jawad, John A. Spertus, Uchechukwu Ikeaba, Stephen John Greene et autres
Importance: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are the first therapy shown to improve clinical outcomes for patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) greater than 40%. Nationwide adoption of SGLT2is in the US since publication of the Empagliflozin …
us
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Mohammad Abdel Jawad, John A. Spertus, Stephen John Greene, Uchechukwu Ikeaba et autres
Introduction: In August 2021, the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved) found that empagliflozin reduced rates of cardiovascular death and hospitalization by 21% in patients with heart failure with mildly reduced ejection fraction of …
us
(code pays fourni par la source)